Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Radiation therapy and anti-CTLA-4 combination therapy can induce meaningful responses in some patients. Adding CD40 may provide additional benefit. Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudqvist, Nils-Petter, Avagyan, Manushak, Chand, Dhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Author‘s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627057/
https://www.ncbi.nlm.nih.gov/pubmed/37937212
http://dx.doi.org/10.1080/2162402X.2023.2275333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627057/
https://www.ncbi.nlm.nih.gov/pubmed/37937212
http://dx.doi.org/10.1080/2162402X.2023.2275333

Ejemplares similares